In our partnerships and licensing focus month, we speak with Mohammed Charki about his role at biotech Hemarina, and the company’s relationship with global drugmaker Sanofi. It’s fair to say ...

In a response to the US SEC decision Sanofi neither admitted nor denied any wrongdoing, but confirmed it will pay $25.2 million and agreed to a two-year period of self-reporting on effectiveness ...

Sanofi is now in “exclusive negotiations” with U.S. private equity firm Clayton, Dubilier & Rice (CD&R) to sell a 50% controlling stake in its consumer health business Opella. With the French ...

Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice, following a last-ditch attempt by a rival bidder to derail the deal ...

With reports swirling about potential interest in Sanofi’s consumer health business, the French pharma has confirmed that a deal is indeed brewing. Sanofi has entered negotiations with private ...

(Bloomberg) -- Bidders for Sanofi’s consumer healthcare unit are revising their offers in part to address concerns around potential liabilities related to a brand that sold talcum powder ...

PARIS, Oct 11 (Reuters) - Sanofi (SASY.PA), opens new tab has entered into talks to sell a controlling 50% stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier ...

Sanofi has asked bidders to revise their proposals for its consumer health unit, people with knowledge of the matter said, as it considers whether to seek a sale or listing of the business. The ...

Sanofi SNY and partner Regeneron REGN announced that the FDA has approved their blockbuster drug, Dupixent, for its sixth indication — chronic obstructive pulmonary disease (COPD) — in the ...

Sept 24 (Reuters) - Sanofi (SASY.PA), opens new tab has received two separate bids from private equity firms for its consumer health unit, which could be valued at 15 billion euros ($16.74 billion ...

Regeneron REGN-0.84%decrease; red down pointing triangle Pharmaceuticals and Sanofi SAN 0.18%increase; green up pointing triangle have won U.S. Food and Drug Administration expanded approval of ...

Bank of America Securities analyst Graham Parry maintained a Buy rating on Sanofi (SNYNF – Research Report) today and set a price target of €122.00. Graham Parry has given his Buy rating due ...